Aptahem AB (publ) (NGM:APTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.095
-0.065 (-5.60%)
At close: Jul 18, 2025
-5.60%
Market Cap20.54M
Revenue (ttm)3.33M
Net Income (ttm)-7.85M
Shares Out17.26M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume36,261
Average Volume22,867
Open1.095
Previous Close1.160
Day's Range1.035 - 1.100
52-Week Range0.560 - 4.500
Beta0.40
RSI53.85
Earnings DateAug 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol APTA
Full Company Profile

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.

Financial Statements

News

There is no news available yet.